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What’s already known about this topic? 
Imiquimod can cause clinical regression of lentigo maligna (LM). 
 
What does this study add? 
The pathological complete regression (pCR) rate is estimated for topical treatment with imquimod for 
LM.  
The accuracy of clinical complete regression with targeted biopsies after imiquimod in predicting 
pCR at subsequent resection of the treated site is investigated. 
The pCR rate dermatologists regard as sufficient to justify the use of imiquimod for LM, adverse 
events, the acceptability of treatment to patients, and patients’ preferences for imiquimod versus 
surgery are documented. 
 
Summary  
Background  
Topical imiquimod is sometimes used for lentigo maligna (LM) in-situ melanoma instead of surgery, 
but frequency of cure is uncertain.  Pathological complete regression (pCR) is a logical surrogate 
marker for cure after imiquimod, although residual LM and atypical melanocytic hyperplasia may not 
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be reliably distinguished.  A trial comparing imiquimod versus surgery might be justified by a high 
imiquimod pCR rate.  
Objectives 
Primary: to estimate pCR rate for LM following imiquimod.  Secondary: to assess accuracy of 
prediction of pCR, using clinical complete regression (cCR) plus negative post-treatment biopsies, 
tolerability, resource use, patients’ preferences; and induced melanoma immunity. 
Methods 
This was a single arm phase II trial of 60 imiquimod applications over12 weeks for LM then radical 
resection.  A pCR rate ≥25/33 would reliably discriminate between pCR rates <60% and ≥85%.  
Clinical response was assessed and biopsies taken after imiquimod.  Patients recorded adverse events 
in diaries.  Patient preference was measured after surgery using a standard gamble tool. 
Results 
The pCR rate was 10/27 (37%, 95% CI 19%, 58%).  The rate of cCR plus negative biopsies was 
12/28 of whom 7/11 had pCR on subsequent surgery.  Median dose intensity was 86.7%. Of surveyed 
patients, 8/16 preferred primary imiquimod over surgery if the cure rate for imiquimod was 80% and 
4/16 if it was ≤50%.    
Conclusions 
The pCR rate was insufficient to justify phase III investigation of imiquimod versus surgery.  Clinical 
complete response and negative targeted biopsies left uncertainty regarding pathological clearance.  
Some patients would trade less aggressive treatment of LM against efficacy. 
 
Trial registration: clinicaltrials.gov identifier: NCT01161888 
 
Key words: Lentigo maligna; lentigo maligna melanoma; imiquimod; surgery; 
pathological complete response; 
 
Introduction 
Lentigo maligna (LM) in-situ melanoma characteristically presents as a slowly developing brown or 
dark brown macule on chronically sun-exposed skin in people over 50 years.  In UK guidelines, 
complete surgical resection is recommended with curative intent
1
.  Five percent of patients with 
typical LM may actually have early invasive melanoma, and the risk of progression to invasive 
lentigo maligna melanoma (LMM) is poorly quantified
2
.  Reported outcomes following surgery vary, 
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including a 30% probability of recurrence at 66-98 months and 1.5% probability of transformation to 
LMM for 81 patients
3
, a crude failure rate (recurrence plus incomplete excision) of 8/102 following 
resection excision with 2mm margins 
4
, and crude recurrence rates of 16/269 (5.9%) following wide 
local excision and 3/154 (1.5%) following Mohs micrographic surgery 
5
.  LM occurs most frequently 
on the head and neck so surgery can cause significant functional and cosmetic disability and, in some 
cases, might not be feasible. 
In 2001, a UK survey showed that the most widely used treatments for LM were surgery, cryotherapy, 
radiotherapy and observation respectively, with non-surgical approaches possibly associated with 
higher recurrence rates and used more for patients >70 years 
6
.  Radiotherapy may have a place in LM 
management, with the aim of trading less invasive intervention and better function and cosmesis, 
against a possibly higher risk of reccurrence or progression to melanoma
7-10
.  No trials have been 
undertaken comparing the outcomes of surgery and radiotherapy or other non-surgical treatments 
11
. 
Imiquimod is a synthetic imidazoquinolin nucleoside analogue available as a 5% strength topical 
formulation with low systemic availability.  Skin application induces local inflammation with 
intensity related to frequency of application.  The use of topical imiquimod as a non-surgical 
treatment for LM has increased following an initial case report in 2000 of disease control for 9 months 
after treatment for 7 months
12
.  Treatment duration is not defined, but 12 weeks is widely used
13
; any 
benefit of longer treatment is unclear.  An effect against LM has been confirmed in subsequent case 
reports and small uncontrolled trials, and in a systematic review
14
, with response rates of 77-90%.  
These studies lacked long term follow up to substantiate disease control and post treatment histology: 
the majority of cases involved biopsy only, with the possibility of sampling error
15-22
. One small study 
used complete surgical excision following imiquimod treatment, and reported complete responses in 4 
out of 6 patients recruited
23
.  A recent retrospective series reported recurrence of LM following 
imiquimod alone in 6/22 patients versus 2/36 having surgery plus imiquimod with mean follow up 
around 40 months
13
. 
The routine use of imiquimod as primary therapy for LM requires proof of efficacy in a large trial 
compared to the outcomes of surgical excision.  We reasoned that, to justify this investment, 
imiquimod treatment should be shown to have a high probability of achieving pathological complete 
response (pCR).  Patients and clinicians might take into account the probability of cure with 
imiquimod and avoiding surgery for a pre-malignant condition, assuming progression is susceptible to 
surveillance. We surveyed UK dermatologists’ opinion regarding what threshold of pCR rate would 
justify routine use of imquimod instead of surgery.  We then designed a single arm trial to justify 
progression to a larger randomised trial.  We sought opinion from trial participants regarding what 
threshold of efficacy they would trade against avoiding surgery, using a structured questionnaire.   
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Patients and Methods 
Participants 
This study was coordinated through the Nottingham Clinical Trials Unit (NCTU), approved by 
Nottingham Research Ethics Committee 2 and eight hospitals recruited between October 2010 and 
August 2011 
To be eligible, patients had to give informed written consent, have a clinical diagnosis of primary 
untreated LM (acquired pigmented macule present >12 months, no change in skin surface texture or 
contour, no palpability, diameter >10 mm, sited on the head or neck) and histologically confirmed LM 
without invasive melanoma in one or more 4mm punch biopsies(s) from the darkest area, reported by 
a pathologist member of a recognised NHS skin cancer Multi-Disciplinary Team.   The LM had to be 
suitable for complete surgical excision using a 5mm lateral margin, and to be easily definable visually 
around its entire circumference. Patients had to be aged >45 years age, fit and willing for surgery, 
without co-existing or adjacent melanoma or non-melanoma skin cancer that might compromise study 
treatment; neither pregnant nor breastfeeding, without hypersensitivity to imiquimod or excipients, 
not taking immunosuppressive medication or participating in another intervention study. 
 
Treatment and follow-up 
Trial interventions and investigations are detailed in figure 1.  The pre-treatment lesion was 
photographed, tattooed at 360, 90, 180 and 270 degrees, outlined in ink and traced on a transparency.  
Training in mapping and tattooing was provided. Patients applied imiquimod (Aldara
®
; MEDA 
Pharmaceuticals) 5 days per week to the visible lesion plus a 2cm margin of normal surrounding skin 
for approximately 8 hours (overnight) and washed off with soap and water as defined in the Patient 
Information Leaflet. After 12 weeks’ treatment, lesions were remapped, biopsied and excised with 
central pathological reporting. The User Opinion Questionnaire Patient was undertaken 12 weeks 
post-surgery by the first 16 patients. 
 
Outcome Measures 
The primary outcome measure was pCR, i.e. absence of LM in both post treatment biopsies and 
resected LM. Imiquimod is an experimental treatment in which post-treatment biopsies would be part 
of assessment of clearance.  Resection is standard of care and, in this trial, permits assessment of LM 
clearance in the whole lesion.  Other pathological outcomes were partial regression (pPR – atypical 
melanocytes present in the epidermis with abnormal distribution and number, but insufficient features 
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to define LM), no change (pNC – presence of LM) or progressive disease (pPD – invasive 
melanoma).  
Clinical outcomes were complete regression (cCR – complete disappearance of abnormal 
pigmentation), partial regression (cPR – reduction in size of pigmented area or obvious reduction in 
its intensity), no change (cNC – appearance identical to that pre-treatment) and progressive disease 
(cPD – increased size or intensity of pigmentation or development of a papule or nodule within LM). 
Targeted biopsies were scored as for the resection specimen, above.  For each individual, the 
prediction of pCR using clinical examination of the mapped regions (weeks 22-24) plus targeted pre-
surgical biopsies was compared with the pathological response in the whole post-treatment resected 
lesion, including any LM outside the clinically mapped margins of disease.   
Patients kept weekly diaries through 12 week’s treatment of adverse reactions, numbers of treatments, 
treatment acceptability on a visual analogue scale and reasons for treatment withdrawal. The number 
of consultations was recorded.   
Following surgery, the participants completed a questionnaire selecting between “I want to have 
imiquimod as first treatment” versus “I want to have surgery now” for 15 hypothetical trial results 
ranging from “imiquimod cures 100% of people; surgery cures 95% of people” to “imiquimod cures 
10% of people; surgery cures 95% of people”.  The explanation included that imiquimod treatment 
included surveillance and deferred surgery in the event of progression. 
Whole blood samples, 40ml, were harvested before and after imiquimod treatment and sent by first 
class post to the Human Biomaterials Resource Centre, Birmingham where peripheral blood 
mononuclear cells (PBMC) were isolated by differential centrifugation and cryopreserved in the 
vapour phase of nitrogen.  Circulating T lymphocyte responses against melanocyte differentiation 
antigens melan A, gp100, tyrosinase and against cancer testis antigens MAGE A1, MAGE A3 and 
NYESO were measured using an ex vivo ELIspot assay 
24
, using overlapping peptides covering the 
whole of each antigen.   
 
Statistical Design and Analysis 
In 2009 all consultant members of the British Association of Dermatologists were asked to mark on a 
visual analogue scale the pCR rate for imiquimod below which “I do not think that imiquimod has any 
potential at all to be used for primary treatment for lentigo maligna” and the pCR rate above which “I 
would be persuaded that imiquimod definitely should be used in the primary treatment of lentigo 
maligna”.  
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This was a single arm phase II trial with a sample size of 33, requiring pCR in 25 participants to 
justify progression to phase III (A’Hern’s method p0=60%, p1=85%, α=5%, 1-β=95%)25.  The bounds 
(p0 and p1) were derived from the upper quartile of pCR thresholds for dermatologists responding to 
the two questions above.  The recruitment target was 40 participants to account for attrition.  
The primary intent-to-treat (ITT) analysis included patients who discontinued imiquimod treatment 
early but proceeded to surgery as per protocol requirements. The pCR rate for patients undergoing 
surgery after imiquimod was estimated with 95% confidence intervals.   
The accuracy of clinical assessment was reported as proportion of cases where cCR plus negative 
biopsies correctly predicted pCR in the subsequent surgical resection specimen.  
Imiquimod dose intensity was calculated from patient diary returns, assuming 60 applications (i.e. 5 
days/week for 12 weeks) to be 100%. 
Patients’ opinions are presented descriptively as the proportion of patients preferring imiquimod over 
surgery in relation to a range of hypothetical cure rates for imiquimod compared to a cure rate for 
surgery of 95%.   
Analyses were performed using Stata v12. 
 
Results 
Responses from 174 UK consultant dermatologists each identified a lower pCR rate below which they 
considered imiquimod to have no potential to treat LM (median 40%; interquartile range (IQR) 30-
60%), and an upper pCR rate above which they could definitely be persuaded of the potential of 
imiquimod to treat LM (median 80%; IQR 60-85%). This was interpreted as indicating only 25% of 
clinicians would reject further investigation of imiquimod as a treatment for LM even if the pCR rate 
was ≥ 60%, and only 25% of clinicians would demand a pCR rate ≥ 85% to justify further 
investigation of imiquimod.  We determined that an observed pCR threshold rate of ≥25/33 would 
reliably exclude a true pCR rate <60% and be powered not to miss a true pCR rate ≥85% (see 
statistical design).   
Twenty-nine patients consented; one withdrew consent and 28 were evaluable.   Median age was 72 
years (IQR 65, 79), 18 male, median size of LM 14mm (IQR 12, 22; range 10-70mm), located on the 
cheek (11), ear (4), forehead (4), nape of neck (1), nose (7) and scalp (2).  The median dose intensity 
over 12 weeks was 86.7%, including three patients stopping treatment early after 4, 8 and 11 weeks, 
and 27 underwent surgical excision post imiquimod (see figure 1).   
Twenty-seven patients were evaluable for the primary outcome. Ten achieved complete pathological 
regression i.e. pCR (37%, 95% CI 19, 58).  None showed LM at the surgical margins.  The patients 
with pCR had achieved imiquimod dose intensity below (7) and above (3) the median of 86.7%.  
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Central review of a single pre-treatment section did not confirm diagnosis of LM in three patients: 
reporting epidermal hyperpigmentation without melanocyte atypia; compound melanocytic naevus; 
and pigmentation and elongated rete ridges without melanocyte atypia.  The pCR rate was 8/24 (33%, 
95% CI 16, 55) if these patients are excluded.  However, priority was given to the fuller 
clinicopathological diagnosis made by the multidisciplinary team at the site. 
Post-treatment resection specimens from a further 9 patients were scored as pPR (i.e. abnormal 
features falling short of defining persistent LM – see methods), 7 had definite residual LM in the 
resection specimen and one had evidence of LMM.   
Clinical evaluation showed that 13/28 patients had complete disappearance of the LM after 
imiquimod, i.e. cCR (46%, 95% CI 28, 66).  Of these, on the post-treatment biopsies, 12 were 
negative for LM and one showed probable residual LM.  Thus clinical and targeted pathological 
evaluation yielded a response rate of 12/28 (43%, 95% CI 24, 63).  Of the 12, one declined resection, 
and 7/11 (64%, 95% CI 31, 89) had pCR on the resection specimen.  Three of 15 who did not achieve 
cCR were observed nonetheless to have pCR (figure 2).  Regarding the 3 with pathological evidence 
falling short of LM on central review of a single diagnostic slide, the outcomes were cCR+pCR, 
cCR+pPR and cPR+pCR.   
Eleven of 29 (38%) patients had a severe local site reaction over the study period; 10 (35%) a 
moderate reaction; 8 (27%) had mild or no reaction.  This peaked at week 4, when 24%, 48%, and 
14% had mild, moderate or severe reactions respectively.  By week 12, 11% and 15% respectively 
still had moderate or severe reactions. Nine of 19 (47%) patients having a moderate or severe local 
site reaction had a pCR, whereas 1/8 (13%) patients with mild or no reaction had a pCR.  Scores for 
acceptability of imiquimod through 12-weeks treatment were reported by 24/29 patients. Dose 
reductions occurred in 5/12 reporting consistently good tolerance and 8/12 reporting variably poor 
tolerance. 
There were 143 adverse events of which 84 (59%) were definitely related to treatment. Medication 
was provided for 117 (82%) of adverse events, and 140 (98%) resolved.  There was no additional 
health service use for 18/29 (62%), 1 unscheduled visit for 8 (28%) and >1 unscheduled visit for 3 
patients (10%).   
Sixteen patients completed the treatment preference survey having experienced both treatments 
(figure 3).  One expressed a strong preference for immediate surgery even with a hypothetical cure 
rate of 100% for imiquimod and 4 strongly preferred imiquimod, tolerating hypothetical cure rates for 
imiquimod ≤ 40% as against 95% for surgery. Half of patients stated they would opt for surgery if the 
cure rate for imiquimod was ≤85%.   
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Imiquimod might work by inducing immune responses against proteins characteristic of melanoma 
cells.  We tested blood samples from 16 patients for such responses of whom 11 had paired samples 
analysed about three months apart.  Target proteins were a number of proteins characteristic of 
melanoma (melan A, gp100, tyrosinase, NYESO1, MAGE A1 and MAGE A3) and, to confirm the 
patients’ cells were working, proteins made by common infections (termed CEPT).  Positive 
recognition of target proteins was defined conventionally as a number of reacting immune cells 
against target proteins that was more than double background immune reactivity.  Twenty seven 
samples from 16 patients were tested and of these 18 from 12 patients made a clear positive 
recognition of the CEPT control. Of the 18 samples with a positive CEPT response, 3 samples from 2 
patients exhibited recognition of a melanoma antigen – both MAGE A1.  Only 6 patients had paired 
samples with positive CEPT recognition on both samples – and of these, 1/6 (who had pPR and cPR) 
showed an amplified response over time, defined as the later recognition value being double that on 
the earlier reading.   
 
Discussion 
It is reasonable to try to spare patients surgery for LM; it can impair function, be disfiguring, and may 
not be feasible.  Non-surgical approaches need not equal surgery in efficacy, provided treatment 
failure could be recognised and surgery undertaken before progression to invasive melanoma.  
Imiquimod promotes an inflammatory state through the activation of macrophages and antigen-
presenting cells via Toll-like receptor 7 signalling, and this localised inflammation can result in 
regression of neoplastic cells
26
. We undertook a single arm phase II trial to determine whether 
investment is justified in a phase III trial comparing imiquimod with surgery.  Clinical regression 
following imiquimod treatment can be followed by relapse
3
.  Therefore, pCR, measured by detailed 
histological examination of LM resected after imiquimod therapy, was selected as surrogate outcome 
measure for possible long term disease control. 
The pCR rate of LM to imiquimod was estimated as 37% (10/27) with confidence intervals indicating 
a true pCR rate >60% was unlikely and >85% very unlikely.  Even had accrual continued to target, 
the highest possible observed pCR rate would have been 16/33, falling short of the pre-planned 
efficacy threshold of 25/33.   
It is improbable that we missed a true effect. Firstly, 27/29 patients completed the study and were 
available for analyses.  Second, 21 of 29 patients had moderate or severe skin inflammation, similar to 
imiquimod toxicity described in case reports of apparently successful imiquimod treatment.  Third, 
median dose intensity was 87% and reduced dose intensity across 12 weeks did not obviously 
associate with lower probability of achieving pCR.  Our pCR rate by detailed pathological 
examination is lower than the >75% regression rate judged by clinical inspection and biopsies in a 
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systemic review of predominantly retrospective series and cases.  Note that these case reports and 
series lacked consistent definition and were susceptible to selection and publication bias
14
.  Recently, 
another trial observed a pCR rate of 20/38 assessable patients with LM treated with imiquimod for 12 
weeks
19
.  A further study compared topical imiquimod with topical imiquimod plus topical tazarotene, 
followed by Mohs excision of the treatment site, with pCR rates of 57 versus 66% respectively 
18
.   
Can we rationally offer imiquimod as first line treatment for LM, reserving surgery for treatment 
failure?  Persistent or progressive clinical abnormality after imiquimod might reasonably be taken to 
indicate proceeding to surgery because only 3/15 such patients had pCR on the resected specimen.  
Conversely, apparent cCR and negative biopsy was an unreliable predictor of pCR, with only 7/11 
cases with cCR plus negative biopsies confirmed as pCR on examination of the excision specimen.  
We recognise that pPR as defined in this study is indistinguishable from actinic melanocytic 
hyperplasia, likely to be present in chronically sub damaged skin
27
.  Thus there is uncertainty whether 
pPR induced by imiquimod might also be a marker for long term clinical remission, which was not 
addressed in our study. 
The efficacy threshold to justify phase III evaluation had been selected to exclude, at the 5% 
probability level, proceeding to phase III despite a true pCR rate of <60% and rejecting further 
investigation despite a true pCR rate >85%.  These thresholds were based on a survey of a large group 
of UK dermatologists.  However, reported opinions were diverse. Only half would definitely reject 
imiquimod treatment even if the true pCR rate was <40% and a quarter would have settled for a true 
pCR rate <60% to definitely proceed to phase III.  Offering imiquimod treatment for a pre-malignant 
condition, with surgery reserved for progression, is a credible strategy for some clinicians despite a 
low pCR rate.  How might patients view this issue?  We surveyed the opinion of the first sixteen 
consecutive patients after each had experienced both imiquimod and surgery and again observed 
diversity of opinion including 4/16 who would still have opted for imiquimod even with the 
probability of cure ≤40%.  However, we had not expected the very high early attrition on accrual in 
which only a fifth of identified patients enrolled for the trial.  This might cause bias favouring 
imiquimod because this attrition itself may reflect patients’ preference for surgery. 
Destroyed cells in a pro-inflammatory milieu might act as an autologous vaccination against 
melanoma, resulting in systemic immunity.  However, we observed our participants generally had a 
frequency of circulating activated T cells  recognising melanoma differentiation or cancer germline 
antigens below the limit of detection with the ex vivo ELIspot assay (~50/10
6
 PBMC) even after 
imiquimod treatment.  A larger sample would be needed to confidently estimate the immune response 
rate and this would also require assays able to detect and measure lower abundance immune 
reactivities. 
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In summary, imiquimod causes local skin adverse reactions which are variably tolerated by patients 
and can be managed by adjusting the frequency of applications.  We estimated the pCR rate of LM to 
imiquimod to be 37%.  This fell short of our pre-defined endpoint that would justify progression to 
randomised comparison versus surgery, assuming that pCR is a prerequisite for term disease control. 
The uncertainty over the interpretation of pPR and the possibility that imiquimod given for a longer 
duration might convert pPR to pCR might still justify such a trial.  We observed that clearance of LM 
clinically and on targeted biopsies missed patients in whom LM was either pathologically persistent 
or in whom pathological persistence was, at best, uncertain.  Based on this, without a larger long term 
trial, the use of imiquimod cannot be recommended as standard first line treatment for LM outside 
exceptional circumstances.   
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Patients with clinical diagnosis of LM
Histological confirmation of LM
Consent
Screen for eligibility
Week 1-12 imiquimod treatment. Daily 
diaries of adverse events and compliance, 
and weekly acceptability.
Week 22-24 Clinical assessment of 
response. 
Biopsies from normal skin, residual 
pigmentation and new pigmentation. 
Surgical excision of entire mapped lesion. 
Assess pathological response in biopsies 
and surgical specimen. Report to local 
investigator.
Week 36 – complete survey of patient’s 
treatment preference
MAP 1: Draw round perimeter of lesion. 
Tattoo edge at 4 compass points. Trace on 
transparent sheet  
MAP 2: Use tattoos and map 1 to define pre-
treatment lesion. Draw round new 
pigmentation. Add 5mm margin to define 
excision area. Trace onto transparent sheet
CENTRAL PATHOLOGICAL REVIEW: Single 
H&E section of pre and post--treatment 
biopsy and 2mm sections through whole 
surgical specimen and post treatment 
biopsies.
IMIQUIMOD TREATMENT: Apply to visible 
skin + 2cm margin normal skin, wash off 
after 8 hours (overnight) 5 days/week.  
Escalate to 7 days/week if well tolerated.  
De-escalate to 3 days/week for intolerable 
inflammatory reactions.  Suspend for 7 days 
at dermatologist’s discretion for poor 
tolerance. 
Identified 157
Enrolled 30 a, b
Treated 29 c
Continued on-trial 28 d
Surgical excision 27 f
Completed questionnaire 16 g
Blood sample
Blood sample
Dose intensity e
median 87%, IQR  71-111%, 
range 33-137%
 
Figure 1.  Trial design and recruitment.   
The sample size was constituted 28 patients evaluated on an intention to treat basis and 27 treated 
patients with post-treatment surgical specimens: (a) 75 patients were ineligible, most commonly 
because LM size <10mm, invasive or recurrent disease, not on head or neck, LM histology not 
conclusive, steroid treatment, ill-defined lesion, inadequate surgical clearance, LM present <12 
months; (b) 52 patients declined trial entry: the most common reasons were burden of travelling (10) 
or time involved (15), delay in surgery (13), and concerns over side effects (3) or lack of efficacy (2) 
of imiquimod; (c) one patient withdrew consent before starting imiquimod; (d) one patient withdrew 
consent after 5.3 weeks treatment; (e) dose intensity was number of imiquimod applications as a 
proportion of expected 60 applications over 12 weeks  (f) one treated patient declined surgery post 
imiquimod; (g) the questionnaire was completed by the first 16 patients on trial. 
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Evaluable patients n=28
cCR 13††*
neg 12††*
pCR
7†/ 11
cPR 11† cNC 3 cPD 1
neg 7†
pCR
3†
Targeted biopsies
pPR
3†/11
pNC
1/11
pos 4
pPR
3
pNC
1
pPR
3
pNC
1
pos 3
neg 1
pPD
1
pNC
2
pNC
1
Clinical assessment
pos 1
pNC
1
Resection
 
Figure 2. Clinical and pathological responses to treatment 
cCR = clinical complete response; cPR = clinical partial response i.e. clinical evidence of 
improvement in the LM falling short of complete regression; cNC = clinical no change; cPD = clinical 
progressive disease; pCR = pathological complete response; pPR = pathological partial response; pNC 
= pathological no change i.e. continuing evidence of LM in specimen; pPD = development of LMM. 
† marks a patient whose local diagnosis of LM was not confirmed on central review of the pre-
treatment biopsy; * marks a patient who declined resection of LM post imiquimod.  
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Figure 3 –User Opinion Questionnaire 
Bar chart depicting the number of patients (y-axis) reporting preference for either surgery (red) or 
imiquimod (blue) for varying hypothetical imiquimod cures rates (x-axis) versus a fixed surgical cure 
rate of 95%.  Patients were surveyed having experienced both treatments.   
 
 
